AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00762216 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AcrySof® Toric intraocular lens
Description: Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
Study NCT02806245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Description: Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped.
Study NCT01784757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 Tablet A
Description: Tablet A formulation of ODM-201
Study NCT01784757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 Tablet B
Description: Tablet B formulation of ODM-201
Study NCT01784757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 capsule formulation
Description: Capsule formulation of ODM-201
Study NCT00731380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
Study NCT03641950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
Study NCT01461213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1
Description: Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
Study NCT03614234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegunigalsidase alfa
Description: Recombinant human alpha galactosidase A
Study NCT03593759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: Oral prednisone/prednisolone tablet
Study NCT03593759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone or Prednisolone
Description: Oral prednisone/prednisolone tablet
Study NCT03593759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral, subcutaneous, or intramuscular methotrexate
Study NCT02062827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M032 (NSC 733972)
Description: A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
Study NCT03353584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Therapy
Description: The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
Study NCT04163484 — intervention group
Intervention type: OTHER
Intervention: Iodinated contrast
Description: Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
Study NCT00912158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Non-invasive mechanical ventilation (CPAP)
Study NCT00912158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP
Description: Non-invasive mechanical ventilation (BIPAP)
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
Study NCT03924856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Study NCT03924856 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
Study NCT03924856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
Study NCT02252874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-paced action video game
Description: 20 hours slow-paced action video games
Study NCT02252874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast-paced action video game
Description: 20 hours fast-paced action video games
Study NCT02252874 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 20 hours leisure activities
Study NCT02423824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
Study NCT00678509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTK peptide mixed with Montanide ISA 51
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT05664048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dry heat application
Description: Self- dry heat application on the foot during menstrual period with pain.
Study NCT00841503 — intervention group
Intervention type: OTHER
Intervention: buckwheat, rice crackers, glucose, sugar substitute
Description: crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
Study NCT02739594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
Study NCT02739594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
Study NCT01333982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amoxycillin, Gentamicin
Description: If referral fails, community management of neonatal sepsis according to clinical algorithm.
Study NCT01333982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: counselling of management of neonatal sepsis in the community according to clinical algorithm.
Study NCT00706173 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10-20 mg PO daily for 4 weeks.
Study NCT03707392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ostomy Education Video
Description: Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
Study NCT03698604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
Study NCT04065022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency
Study NCT00664092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residential
Description: living in a democratic, resident-run setting
Study NCT00664092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residential
Description: Professionally-run substance abuse recovery setting
Study NCT01734941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSO
Description: There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
Study NCT01734941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01608789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtue® Male Sling
Description: The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
Study NCT01073527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline-salbutamol combination
Description: hypertonic saline 5% with 0.5cc salbutamol
Study NCT01073527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline-salbutamol combination
Description: normal saline - 4cc with salbutamol 0.5cc
Study NCT02817555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin > 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.
Study NCT02817555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin >150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.
Study NCT00443378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE+
Description: CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
Study NCT00443378 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: CARE+
Description: CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
Study NCT05158452 — intervention group
Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend a focus group
Study NCT03394079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous Coronary Intervention
Study NCT03394079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous Coronary Intervention
Study NCT03803904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spin
Description: The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
Study NCT03803904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin
Description: The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
Study NCT02543398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ridge preservation
Description: Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
Study NCT00928473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A family-centered, multidisciplinary obesity treatment program
Description: The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
Study NCT01137331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K301
Description: Liquid- applied once daily prior to bed
Study NCT01137331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid- applied once daily prior to bed
Study NCT03154723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
Study NCT01441440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75 mg/day (fixed dose)
Description: Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
Study NCT01441440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
Description: Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
Study NCT03707392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Standard ostomy education
Description: Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
Study NCT03862534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
Study NCT03862534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Description: After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
Study NCT01644149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratis Jet Injector
Description: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study NCT01644149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle and Syringe
Description: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study NCT01644149 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study NCT01644149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study NCT02241109 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: progression monitoring by echocardiography
Study NCT00704496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine is a 240 mg PO per day
Study NCT00704496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine is a 240 mg PO per day
Study NCT01954914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
Study NCT02001155 — intervention group
Intervention type: PROCEDURE
Intervention: Water Drinking Test
Description: The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
Study NCT00648245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 75 mg of BIO-11006 administered once per day for 21 days by nebulizer
Study NCT00648245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 150 mg of BIO-11006 administered once per day for 21 days by nebulizer
Study NCT00648245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
Study NCT00648245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once daily for 21 days by nebulizer
Study NCT00648245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006
Description: 125 mg BIO-11006 given twice per day for 21 days by nebulizer
Study NCT04755621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Core stability exercises
Study NCT04755621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rocabado Exercises
Description: Exercises for Temporomandibular Disorders